Bosevska G, Kuzmanovska G, Sikole A, Dzekova-Vidimilski P, Polenakovic M
Institute for Public Health of R. Macedonia, Skopje, R. Macedonia.
Prilozi. 2009 Dec;30(2):159-74.
The aim of the work was to detect the serum prevalence of HBV, HCV and HIV infections in patents with ESRD (end stage renal disease) on haemodialysis treatment from two dialysis units.
178 patients from two haemodialysis units in Skopje (Department of Nephrology and HDC Zelezara) who received haemodialysis treatment over the period January to July 2005 were involved in a cross-sectional analysis. Patients were aged 31 to 77 (mean 54) years. Serum samples were used for: detection of markers for hepatitis B - HBs antigen (Ag), HBsT antibody (Ab) and HBcT Ab with chemiluminescent enzyme immunoassay; detection of HIV Ab and HCV Ab with the ELISA method; detection of HCV RNA with qualitative PCR. Statistical analysis was done only of patients with complete serological investigations (HCV, HBV and HIV).
Detectable markers for HBV infections were found in 43 patients (24.16%). Of these, 3 patients (1.68%) had positive HbsAg. Previous exposure to HBV was seen in 40 patients (22.47%). 57 patients (32.02%) had detectable markers (HCV Ab and/or HCV RNA) for HCV infections. 39 patients (21.91%) had detectable HCV RNA. 24 patients were positive for HBV and HCV markers. The total number of patients with anti HCV Ab was 56 (31.46%). All investigated patients were negative for anti HIV Ab. There is a positive correlation between AST elevation and HCV RNA (r = 0.342, p = 0.023) as well between AST elevation and HBsT (r = 0.300, p = 0.048). A positive correlation was found between ALT elevation and HCV RNA (r = 0.374, p = 0.012). A Chi square test found significance between the time on dialysis and detection of HCV RNA (chi-square 7.771, p = 0.05).
The results of our survey presented a prevalence of 24.16% of HBV and a prevalence of 32.02% of HCV in patients with renal failure on haemodyalisis programmes from two dialysis units for the six month period. HIV was not detected among the investigated patients. Immunoenzyme tests were the method of choice for the screening programme. The use of the PCR for detection of nucleic acid of viruses that can be the cause of infection for these persons is especially important. Timely detection of HBV, HCV and HIV infection among haemodyalisis patients is necessary for the due performance of therapy, as well as for taking preventive measures for the protection of other patients and staff in the haemodyalisis unit.
本研究旨在检测来自两个透析单位接受血液透析治疗的终末期肾病(ESRD)患者中乙肝病毒(HBV)、丙肝病毒(HCV)和人类免疫缺陷病毒(HIV)感染的血清流行率。
对2005年1月至7月期间在斯科普里两个血液透析单位(肾脏病科和泽莱扎拉血液透析中心)接受血液透析治疗的178例患者进行横断面分析。患者年龄在31至77岁(平均54岁)之间。血清样本用于:采用化学发光酶免疫分析法检测乙肝标志物——乙肝表面抗原(HBsAg)、乙肝表面抗体(HBsAb)和乙肝核心抗体(HBcAb);采用酶联免疫吸附测定法(ELISA)检测HIV抗体和HCV抗体;采用定性聚合酶链反应(PCR)检测HCV RNA。仅对血清学检查(HCV、HBV和HIV)完整的患者进行统计分析。
43例患者(24.16%)检测到HBV感染标志物。其中,3例患者(1.68%)HBsAg呈阳性。40例患者(22.47%)既往有HBV暴露史。57例患者(32.02%)检测到HCV感染标志物(HCV抗体和/或HCV RNA)。39例患者(21.91%)检测到HCV RNA。24例患者HBV和HCV标志物呈阳性。抗HCV抗体阳性的患者总数为56例(31.46%)。所有受调查患者抗HIV抗体均为阴性。谷草转氨酶(AST)升高与HCV RNA之间存在正相关(r = 0.342,p = 0.023),AST升高与乙肝表面抗体(HBsAb)之间也存在正相关(r = 0.300,p = 0.048)。谷丙转氨酶(ALT)升高与HCV RNA之间存在正相关(r = 0.374,p = 0.012)。卡方检验发现透析时间与HCV RNA检测之间存在显著差异(卡方值7.771,p = 0.05)。
我们的调查结果显示,在来自两个透析单位接受血液透析治疗的肾衰竭患者中,六个月期间HBV感染率为24.16%,HCV感染率为32.02%。在受调查患者中未检测到HIV。免疫酶试验是筛查项目的首选方法。采用PCR检测可能导致这些患者感染的病毒核酸尤为重要。及时检测血液透析患者中的HBV、HCV和HIV感染对于适当开展治疗以及采取预防措施保护血液透析单位的其他患者和工作人员非常必要。